Trial NCT04479163
Publication Libster R, NEJM, 2021
Primary outcome on the report: Development of severe respiratory disease defined as a respiratory rate (RR)≥ 30 and/or an O2 sat < 93% when breathing room air determined between 12 hours after infusion of the investigational product (IP) and day 15 of study participation